Latest News and Press Releases

New DTU study uses Cytosurge’s CellEDIT to overcome editing barriers in fragile skin cells, decoding dermokine’s role in wound healing and skin cancer.

Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial ...

Access it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of its latest CEO Corner segment,...

Both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP

The Alberta Cancer Foundation is investing $35-million to advance cancer clinical trials in Alberta.

ICP-B208 is InnoCare's second ADC from its in-house platform to enter clinical development. There are no approved CDH17 targeted ADCs globally.

REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Founder's Purchase of ADSs

Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy

                                                                          Urteste S.A. Receives U.S. Patent for the Panuri Test Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange:...